Integragen (ALINT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Integragen (ALINT) has a cash flow conversion efficiency ratio of -1.910x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-645.51K ≈ $-754.67K USD) by net assets (€338.04K ≈ $395.20K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Integragen (ALINT) net asset quality to measure how much of total assets are equity-financed.
Integragen - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how Integragen's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Integragen to evaluate the quality of earnings relative to operating cash generation.
Integragen Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Integragen ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Real Good Food Company, Inc.
NYSE:RGFC
|
N/A |
|
Maven Income and Growth VCT 4 PLC
LSE:MAV4
|
-0.007x |
|
TrustBIX Inc
V:TBIX
|
0.061x |
|
BioNeutra Global Corp
V:BGA
|
-0.004x |
|
Sarawak Cable Bhd
KLSE:5170
|
0.002x |
|
Satis Group S.A.
WAR:STS
|
0.000x |
|
Insplorion AB
ST:INSP
|
-0.139x |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Integragen (2012–2022)
The table below shows the annual cash flow conversion efficiency of Integragen from 2012 to 2022. For the full company profile with market capitalisation and key ratios, see ALINT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €2.20 Million ≈ $2.57 Million |
€403.11K ≈ $471.28K |
0.183x | -2.75% |
| 2021-12-31 | €2.19 Million ≈ $2.56 Million |
€411.78K ≈ $481.41K |
0.188x | -9.62% |
| 2020-12-31 | €2.17 Million ≈ $2.54 Million |
€452.69K ≈ $529.24K |
0.208x | +104.19% |
| 2019-12-31 | €2.51 Million ≈ $2.93 Million |
€256.10K ≈ $299.41K |
0.102x | +109.82% |
| 2018-12-31 | €2.79 Million ≈ $3.27 Million |
€135.90K ≈ $158.88K |
0.049x | +55.07% |
| 2017-12-31 | €3.93 Million ≈ $4.60 Million |
€123.30K ≈ $144.15K |
0.031x | -61.91% |
| 2016-12-31 | €1.28 Million ≈ $1.50 Million |
€105.62K ≈ $123.49K |
0.082x | +102.29% |
| 2013-12-31 | €691.87K ≈ $808.87K |
€-2.49 Million ≈ $-2.91 Million |
-3.592x | -693.04% |
| 2012-12-31 | €3.24 Million ≈ $3.78 Million |
€-1.47 Million ≈ $-1.71 Million |
-0.453x | -- |
About Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and o… Read more